Calamos Advisors
BHVN

Calamos Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Calamos Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-27,800
Closed -$3.3M – 1260
2022
Q1 		$3.3M Buy
+27,800
New +$3.47M 0.01% 808
2021
Q1 		– Sell
-21,361
Closed -$1.83M – 994
2020
Q4 		$1.83M Buy
21,361
+3,783
+22% +$321K 0.01% 645
2020
Q3 		$1.14M Buy
+17,578
New +$1.15M 0.01% 641

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Calamos Advisors's BHVN Position: Q2 2022 in Review

Calamos Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 27,800 shares — an estimated $3.3M sold.

Calamos Advisors first reported a position in BHVN in Q3 2020 and held it in 3 quarters. The position peaked at $3.3M in Q1 2022. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

  • Calamos Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
  • Calamos Advisors sold 27,800 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $3.3M.
  • Calamos Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2020 and held it in 3 quarters.
  • Calamos Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $3.3M in Q1 2022.
  • 329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Calamos Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.